Anti-peptide vaccination may be more effective in cancer cells with low HER2 expression because these cells exhibit high MHC class I expression and are more easily recognized by CD8+ T cells, allowing for elimination of tumor cells (46). Here, ERBB2 is linked to neoplasm.